Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q2 2015 · 10-Q
Revenue$20.04K$20.04K−82.2% vs Q2 2014 Net Income-$2.05M-$2.05MN/M vs Q2 2014 EPS Diluted-$0.19-$0.19N/M vs Q2 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$276,522N/M Margins · derivedGross margin45.1%+7.3 pt vs Q2 2014
Net margin-10235.1%−9480.7 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 19, 2015 · 50 d after period end